SAGE Therapeutics (SAGE) Posts Q4 Loss of ~$1.57/Share

SAGE Therapeutics (NASDAQ: SAGE) reported Q4 EPS of about ($1.57), $1.13 worse than the analyst estimate of ($0.44).

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.

You May Also Be Interested In

• Activist investor presses Xerox to review financial services arm - Bloomberg
• UBS upgrades Lockheed Martin to Buy, sees 26% upside on missile growth
• Chime to acquire Stride Bank for $590M in cash